Wedbush Reiterates “Outperform” Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a report issued on Thursday,RTT News reports. They currently have a $36.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 366.93% from the company’s previous close.

A number of other research analysts have also weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, Scotiabank reduced their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Stock Up 0.8 %

KURA opened at $7.71 on Thursday. The company has a market capitalization of $599.56 million, a PE ratio of -3.27 and a beta of 0.78. The firm has a 50-day simple moving average of $8.16 and a two-hundred day simple moving average of $13.88. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 over the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Kura Oncology by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after acquiring an additional 5,788 shares during the period. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 21.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock worth $924,000 after purchasing an additional 8,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after purchasing an additional 7,722 shares during the period. Intech Investment Management LLC bought a new stake in Kura Oncology during the 3rd quarter valued at $298,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after buying an additional 14,106 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.